Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J/Merck Developing Mevacor 20 Mg As OTC For Moderate Risk Group

This article was originally published in The Tan Sheet

Executive Summary

J&J/Merck's second try at an Rx-to-OTC switch for Mevacor (lovastatin) involves a 20 mg dose targeted at a moderate to intermediate risk group, according to VP-Regulatory & Scientific Affairs Edwin Hemwall, PhD
Advertisement

Related Content

NDAC/Endocrinologic Drug Joint Panel Meeting Likely To Focus On Statins
Statin Benefits Outweigh Liver Toxicity Risks In Most Patients – Editorial
Advisory OTCs? GSK Weighs Third Class Paradigm With Xenical In Mind
Heart Disease Is Largest Driver Of Health Costs – Health Affairs Study
Physicians “Cautiously Open” To OTC Statins – NLA Survey
JAMA Letters Question Statin Therapy Gap Between High/Low Doses
Zocor Ad Targets Diabetics With Reference To Heart Protection Study
McNeil Reaches Consumer Cholesterol Testing Licensing Deal With IMI
Round Two: Mevacor Switch Will Need To Quiet Undertreatment Questions
Mevacor Study Comparing Rx, OTC Use Is Among FDA Panel Suggestions

Topics

Advertisement
UsernamePublicRestriction

Register

PS096829

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel